As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
HOME > ORGANIZATION
ORGANIZATION
- Asian Industry Groups Agree to Use Common Site Master File for Plant Inspections
April 16, 2018
- PhRMA Chief Warns of Serious Implications for Japan Market after 2018 Pricing Reform
April 13, 2018
- Company Category Criteria for Price Maintenance Premium Tough on Ophthalmic Drug Makers: Industry Group
April 9, 2018
- Japan CRO Association Members Deliver Actual 8.1% Sales Surge in 2017
April 5, 2018
- GHIT Fund to Make New Investment of 1.66 Billion Yen for Development of Therapies and Vaccines
March 30, 2018
- 100 Infusion Products Got Price Raises under Unprofitability Re-Pricing, but Drastic Pricing Reform Still Necessary: IV Solution Society
March 26, 2018
- Americas Chief James Robinson Leaves Astellas, What Will Happen to PhRMA Treasurer Seat?
March 20, 2018
- Annual Re-Pricing Key Focus Issue for Japan Pharma Trade Group in FY2018
March 16, 2018
- Hodanren Opposes Generic Use Requirement for Welfare Recipients
February 23, 2018
- JPMA to Compile Counterproposal for New PMP Scheme ASAP
February 16, 2018
- Astellas Becomes 1st Japan Maker to Join PhRMA Leadership
February 14, 2018
- Private Univ. Group Encourages “Single-Product, Single-Price” Deals in Response to New Distribution GL, Tougher Medical Fee Cut Rules
February 9, 2018
- “Unprecedented Reforms to Take Place as a Result of Chuikyo’s Leadership”: JMA Pres. Yokokura
February 8, 2018
- Japan Could Miss Out on Wave 1 of Drug Development, Re-Do and Do Right on PMP: PhRMA
January 30, 2018
- Japan Pharma Leader Says Pricing Overhaul Would Not Expand Drug Lag
January 18, 2018
- Exclude 50 Yen or Lower Price Generics from “Off-Year” Re-Pricing: JGA Chief
January 15, 2018
- Pharma Leaders Air Bleak Outlook on New PMP Scheme at New Year’s Reception
January 10, 2018
- JPMA to Call for Improvements in PMP-Eligibility Criteria, Company Requirements: Chief
December 22, 2017
- Continued Discussions Needed for PMP-Eligible Products, Company Criteria: FPMAJ/JPMA
December 22, 2017
- PhRMA/EFPIA Rap Japan’s Drug Pricing Reform, Warn of Grave Consequences
December 21, 2017
ページ
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
An adult man who completed the administration of an investigational drug in a Japan PI study conducted by Eisai has died. Whether there was a causal relationship between the drug and the subject’s death remains unclear at the present time,…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Jascha Heifetz, widely regarded as one of the greatest violinists of all time, was once stopped, on 57th Street in Manhattan, by a pedestrian asking, “Could you tell me how to get to Carnegie Hall?” Heifetz pondered the question for…